Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SARS-CoV-2-IN-32 is a COVID-19 inhibitor. SARS-CoV-2-IN-32 exhibits good binding affinity (-8.8 Kcal/mole) for the COVID-19 major protease (Mpro) (PDB ID: 6LU7) and has anti-proliferative effects on cancer cells. IN-32 can be used to study cancer and COVID-19.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約6-8 週間 | ¥ 491,500 |
50 mg | 約6-8 週間 | ¥ 639,500 |
100 mg | 約6-8 週間 | ¥ 808,000 |
説明 | SARS-CoV-2-IN-32 is a COVID-19 inhibitor. SARS-CoV-2-IN-32 exhibits good binding affinity (-8.8 Kcal/mole) for the COVID-19 major protease (Mpro) (PDB ID: 6LU7) and has anti-proliferative effects on cancer cells. IN-32 can be used to study cancer and COVID-19. |
分子量 | 481.5 |
分子式 | C27H23N5O4 |
CAS No. | 96068-42-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
SARS-CoV-2-IN-32 96068-42-7 Inhibitor inhibitor inhibit